139 related articles for article (PubMed ID: 15822162)
1. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
Wang LR; Huang MZ; Xu N; Shentu JZ; Liu J; Cai J
J Zhejiang Univ Sci B; 2005 May; 6(5):446-50. PubMed ID: 15822162
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Wang LR; Liu J; Huang MZ; Xu N
J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
[TBL] [Abstract][Full Text] [Related]
4. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Caffo O; Fallani S; Marangon E; Nobili S; Cassetta MI; Murgia V; Sala F; Novelli A; Mini E; Zucchetti M; Galligioni E
Cancer Chemother Pharmacol; 2010 May; 65(6):1197-202. PubMed ID: 20140616
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
[TBL] [Abstract][Full Text] [Related]
8. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Kroep JR; Giaccone G; Voorn DA; Smit EF; Beijnen JH; Rosing H; van Moorsel CJ; van Groeningen CJ; Postmus PE; Pinedo HM; Peters GJ
J Clin Oncol; 1999 Jul; 17(7):2190-7. PubMed ID: 10561275
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Shord SS; Faucette SR; Gillenwater HH; Pescatore SL; Hawke RL; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2003 Apr; 51(4):328-36. PubMed ID: 12721761
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
14. [Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Wang LR; Zhang GB; Huang MZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 36(4):391-5. PubMed ID: 17717833
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.
Steinherz PG; Seibel NL; Ames MM; Avramis VI; Krailo MD; Liu-Mares W; Reid JM; Safgren SL; Reaman GH
Leuk Lymphoma; 2002 Oct; 43(10):1945-50. PubMed ID: 12481889
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Carmichael J; Allerheiligen S; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Wang LR; Huang MZ; Zhang GB; Xu N; Wu XH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):601-7. PubMed ID: 17549479
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
